Recombinant Rat IL-23 alpha Protein , N- His & GST

Interleukin-23 (IL-23) is a cytokine that plays a crucial role in the immune response, particularly in the differentiation and maintenance of pro-inflammatory T-helper 17 (Th17) cells. Elevated levels of IL-23 have been implicated in a variety of inflammatory diseases, including psoriasis, inflammatory bowel disease, and multiple sclerosis, positioning it as a significant target for therapeutic intervention. Research on IL-23 has gained momentum as understanding its biological functions can lead to novel treatments for these conditions. The IL-23 alpha subunit, a component of the IL-23 heterodimer, is of particular interest because it is essential for the stability and activity of the cytokine. Recombinant forms of IL-23 alpha protein have been developed for both research and therapeutic purposes, serving as crucial tools in elucidating the mechanisms of IL-23-mediated signaling pathways and in testing new therapeutic agents that can block or modulate IL-23 activity. The ongoing studies on IL-23 alpha not only aim to further comprehend its role in immune regulation but also seek to validate its efficacy and safety in clinical settings, enhancing the prospects of targeted therapies against inflammatory diseases. Overall, the exploration of IL-23 alpha recombinants continues to advance our understanding of immune dysregulation and contribute to the development of innovative treatment strategies.